Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the ‘Spirit Molecule’
February 2, 2021 (Investorideas.com Newswire) Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that